Best practice working with patients in R & D
Updated: May 3, 2019
In this four part video series of If Medicines Could Talk© , European Policy Health Consultant, Tamsin Rose, sets the scene for best practice working with patients and patient groups in R and D.
Nick Hicks: Welcome to this episode of If Medicines Could Talk, and today I'm speaking with Tamsin Rose, who is a longterm consultant in advocacy and communications who has helped patient groups and similar organizations to determine their strategic direction.
Tamsin Rose: Since 2001, I've been working on public health. And over that time, obviously I've worked with a very wide range of organizations. But specifically within the patient sector, autoimmune diseases like rheumatoid arthritis, lupus, chronic diseases like cancer, diabetes, the infectious disease area, so tuberculosis, hepatitis, HIV.
Nick Hicks: Briefly explain a little bit about what you do.
Tamsin Rose: Okay. I start by listening. I find out from an organization, what are their challenges, what are their problems, and where do they see themselves, what do they want to achieve? And then I help them anywhere along the spectrum of things they need to do. And that might be helping them organize the way they work together, their communications, their messages, how they speak to the outside world.
Subjects covered in this series:
1. Get quicker uptake and more valuable output by using capacity building strategies.
2. Which patient groups are the more ready and willing to work in research.
3. The dangers of a tokenistic approach.
4. How Brexit could affect your patient engagement strategy.